Detalhe da pesquisa
1.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
N Engl J Med
; 382(7): 610-621, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31825192
2.
A Comparison of Seven Oncology External Control Arm Case Studies: Critiques From Regulatory and Health Technology Assessment Agencies.
Value Health
; 25(12): 1967-1976, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35760714
3.
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Lancet
; 394(10197): 478-487, 2019 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31229240
4.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Lancet Oncol
; 20(6): 816-826, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31047803
5.
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 20(7): 984-997, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31175001
6.
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Lancet Oncol
; 18(11): 1512-1522, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29037983
7.
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.
Oncotarget
; 6(16): 14139-52, 2015 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-25944621
8.
Development and validation of a real-time PCR assay for the detection and quantitation of p53 recombinant adenovirus in clinical samples from patients treated with Ad5CMV-p53 (INGN 201).
J Virol Methods
; 114(1): 55-64, 2003 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-14599679
9.
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Eur J Cancer
; 48(2): 218-25, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22056637
10.
Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).
Cancer Chemother Pharmacol
; 65(4): 671-7, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19621225
11.
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
J Clin Oncol
; 25(21): 3137-43, 2007 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-17634493
12.
Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck.
Anticancer Drugs
; 15(4): 331-40, 2004 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15057136